BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Exclusion Criteria

• •Patients with the Hodgkin variant of RS
• •Patients with previously treated RS
• •History or presence of clinically relevant disorder affecting the central nervous system (CNS)
• •Known active DLBCL in the CNS (confirmed by cerebrospinal fluid analysis)
• •Steroids treatment (≥ 20 mg for one week) before inclusion
• •HSCT within 6 months before inclusion
• •Active graft-versus-host disease
• •History of other malignancies, except: i) malignancy treated with curative intent and with no recurrence over the last 5 years ii) adequately treated non-melanoma skin cancer without evidence of disease iii) adequately treated carcinoma in situ without evidence of disease
• •History of human immunodeficiency virus
• •Hepatitis B or C seropositivity (unless clearly due to vaccination)
• •Pregnant or breastfeeding women
• •Unwilling or unable to participate in all required study evaluations and procedures.
• •Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form and authorization to use protected health information (in accordance with national and local subject privacy regulations)
• •Abnormal screening laboratory values as defined as following: a) serum glutamate oxaloacetate transaminase and/or serum glutamate pyruvate transaminase and/or alkaline phosphatase \> or =5 x upper limit of normal (ULN); b) Total bilirubin \> or = 1.5 x ULN, unless due to Gilbert's disease; c) Creatinine \> or = 2.0 x ULN or creatinine clearance \<50 mL/min (calculated).
• •Fertile male and female patients who cannot or do not wish to use an effective method of contraception during treatment and for 48h after the final treatment used for the purposes of the study
• •Treatment with other investigational agent or participating to another trial within 30 days prior to entering the study
• •No affiliated to social security